Wilms’ tumor suppressor gene (WT1) suppresses apoptosis by transcriptionally downregulating BAX expression in immature rat granulosa cells by Minji Park et al.
Park et al. Journal of Ovarian Research 2014, 7:118
http://www.ovarianresearch.com/content/7/1/118RESEARCH Open AccessWilms ? tumor suppressor gene (WT1) suppresses
apoptosis by transcriptionally downregulating
BAX expression in immature rat granulosa cells
Minji Park, Yuri Choi, Hyeonhae Choi and Jaesook Roh*Abstract
Background: The important role of WT1 in early folliculogenesis was evident from its restricted expression pattern
in immature follicles and from its involvement in transcriptional control of inhibin-α and FSH receptor. There is also
considerable evidence that WT1 is a potent inhibitor of apoptotic cell death in the developing kidney and male
germ cells, suggesting that it could play a role in the regulation of follicle survival. Therefore, we evaluated if WT1
involves in cell survival of granulosa cells (GCs) during the FSH-independent stage.
Methods: GCs were obtained from small preantral follicles of immature rat ovary. Bax and bcl-2 mRNA and protein
levels in GCs transfected with WT1 (−KTS) or WT1 (+KTS) were analyzed by Real-time RT-PCR and immune-blotting
analysis. Cell viability was measured with MTT assays and apoptosis was analyzed with caspase 3/7 activity and TUNEL
assay. The mechanism by which WT1 regulates Bax expression was investigated using Bax promoter-luciferase reporter
assay and ChIP assays from GCs.
Results: Here, we showed that WT1 (−KTS) suppressed endogenous Bax transcript and protein expression, and this
inhibition resulted from direct binding of WT1 in the Bax promoter region in vivo. In addition, anti-apoptotic effects of
WT1 (−KTS) were demonstrated based on MTT assays, a sensitive bioluminescence caspase 3/7 assay and TUNEL assays.
On the other hand, WT1 has no role on bcl-2 expression in GCs.
Conclusion: These findings suggest that activation of WT1 is necessary for maintenance of GC survival during early
stage of follicles and WT1 can play a role in protecting apoptosis through the regulation of upstream activator (Bax), as
well as through regulation of downstream effecter (caspases 3 and 7).
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The fate of the follicles depends on the balance between
anti- and pro-apoptotic factors that determine the rate
of granulosa cell (GC) apoptosis. Although apoptosis
can occur at any stage of follicular development, a grow-
ing follicle is more prone to apoptosis than arrested or
early-stage follicles, and the majority of follicles become
atretic during the antral stage [1]. The factors regulating
follicular growth and survival appear to differ for small
follicles and the more differentiated antral follicles. Fur-
ther study of how the apoptotic genes are regulated may* Correspondence: rohjaesook@hanyang.ac.kr
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unless otherwise stated.answer the questions of why quiescent follicles are not
apoptotic, and why early-stage follicles are relatively re-
sistant to apoptosis until they receive appropriate signals
to initiate further growth.
The important role of WT1 in early folliculogenesis is
evident from the fact that its expression is restricted to
immature follicles [2] and from its involvement in the
transcriptional control of ovarian marker genes that en-
code inhibin-α [3] and the follicle stimulating hormone
(FSH) receptor [4]. There is also considerable evidence
that WT1 is a potent inhibitor of apoptotic cell death in
the developing kidney [5] and male germ cells [6], sug-
gesting that it could play a role in the regulation of fol-
licle survival. However, there is no direct evidence of an
anti- or pro-apoptotic function of WT1 protein, and itsis an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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understood.
We hypothesized that WT1 was required to regulate
the transcription of the genes that provide a cell survival
advantage to the GCs of the early preantral follicles in
the FSH-independent stages of development. Here we
investigated whether the expression of WT1 was associ-
ated with changes in the expression of two apoptosis re-
lated genes, bcl-2 and Bax, which function as the final
common mediators of life and death [7]. In addition, we
examined the effects of WT1 on GC viability and apop-
tosis. A better understanding of the cellular signals that
induce or prevent apoptosis may help us control follicu-




Immature female Sprague ? Dawley rats were obtained
from Samtako Biokorea (Kyunggi, South Korea). All ani-
mals were housed under controlled humidity, temperature,
and light conditions, and fed standard rat chow ad libitum.
Animal care was consistent with institutional guidelines,
and the Hanyang University ACUC committee approved
all procedures involving animals (HY-IACUC-09-034).
Preparation and culture of granulosa cells
GCs were obtained by puncture of the ovaries of imma-
ture 25-day-old rats (body weight, 55 ? 65 g) previously
primed with diethylstilbestrol. The ovaries were punc-
tured in Leibovitz L-15 medium. Ovarian debris was re-
moved, and the remaining medium containing GCs was
collected after low-speed centrifugation at 500 ? g for
10 min. The GCs were dispersed by repeated washing
and suspended in growth medium (McCoy? s 5a supple-
mented with 2 mM L-glutamine, 100 U/mL penicillin,
and 100 μg/mL streptomycin). McCoy? s 5a medium
(modified) and Leibovitz L-15 medium were obtained
from GIBCO (Santa Clara, CA, USA). Penicillin and
streptomycin were obtained from Sigma (St. Louis, MO,
USA). Recombinant human FSH (Org 32489E) was from
NV Organon (Oss, The Netherlands).
Plasmid construction and transfection
Full-length mouse WT1 cDNA (−KTS) or (+KTS) was
subcloned into the pCMV5 expression vector under the
control of the CMV promoter and the GH-pA signal,
[WT1 (−KTS)] or [WT1 (+KTS)]. Granulosa cells (5 ? 10 5
viable cells/well) were grown in culture medium supple-
mented with 10% fetal bovine serum (FBS) for 2 h. The
medium was then changed to serum-free medium and the
cells were transfected with expression and/or reporter
plasmids using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer ? sinstructions. The cells were used for the experiment at
sixteen hours after transfection. At the end of growth
they were frozen for RNA or protein extraction.
To evaluate promoter activity induced by WT1 overex-
pression, cells were cotransfected with the Bax (−2673
to +1 bp of the 5 ? flanking sequence of the mouse Bax
gene) promoter-luciferase reporter plasmid Bax-Luc
(250 ng) with WT1 (−KTS), or WT1 (+KTS) cDNA
(100 ng) or empty vector as a balancer. The p-Rous sar-
coma virus (RSV)-β-galactosidase (gal) vector (50 ng)
containing the lacZ gene encoding β-gal driven by the
RSV long terminal repeat was used as an internal con-
trol to correct for differences in transfection efficiency.
Sixteen hours after transfection, the cells were incubated
in FSH (50 ng/mL) or control medium for 16 ? 24 h, then
harvested, lysed, and assayed for luciferase activity.
To harvest the cells, lysis buffer (200 μL) (Promega)
was added to each well and 30 μL of supernatant was used
to detect luciferase activity on a Monolight 2010 lumin-
ometer (Analytical Luminescence Laboratory, San Diego,
CA, USA). 50 μL of cell lysate was also used to measure
β-gal activity. The activity of the promoter is expressed
as the ratio of relative light units /β-gal activity.
Real time RT-PCR
Total RNA was isolated with an RNeasy extraction kit
(Qiagen Inc., Valencia, CA, USA). 1 μg aliquots of total
RNA were annealed (5 min at 70?C) to oligo(dT) 18 primers
and reverse transcribed using an Advantage RT-for-PCR
kit (BD Biosciences; Clontech, Palo Alto, CA, USA). The
primers were designed for the mRNA sequences of Bax
and bcl-2 using the Primers Express program (PE Applied
Biosystems, Foster City, CA, USA): Bax forward, 5? -TGT
TTGCTGATGGCAACTTC-3? and reverse, 5? -GATCAG
CTCGGGCACTTTAG-3? (GenBank accession no. NM_
017059.1); bcl-2 forward, 5? -GGGATGCCTTTGTGGA
ACTA-3 ? and reverse, 5 ? -CTCACTTGTGGCCCAGGT
AT-3? (GeneBank accession no. NM_016993.1). GAPDH
was amplified using 5 ? -GCTGGCATTGCTCTCAAT
GACA-3 ? (forward) and 5? -TCCACCACCCTGTTGC
TGTA-3? (reverse) (GenBank accession no. NM_017008)
to normalize each reaction (amplification product sizes
104, 138, and 83 bps for Bax, bcl-2, and GAPDH, re-
spectively). Real-time polymerase chain reactions were car-
ried out in 25 μL volumes using SYBR Green Supermix
(BioRad, Hercules, CA, USA) in an iCycler Thermal Cycler
(BioRad). Samples were run in triplicate in 96-well optical
plates (BioRad) and mean values were compared with the
control values (empty vector-transfected cells) to calculate
the relative amount of transcript.
Western blotting
To investigate Bax and bcl-2 protein regulation by WT1,
GCs transfected with WT1(−KTS) or WT1(+KTS) were
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with cold PBS before lysis in Laemmli buffer containing
β-mercaptoethanol. The cells were gently sonicated on
ice for 15 sec with an MSE sonicator (Sanyo Corp.,
Osaka, Japan) and boiled for 3 min. Proteins were sepa-
rated on 8% SDS-PAGE gels and electroblotted onto
Hybond-P membranes (Amersham Pharmacia Biotech,
Arlington Heights, IL, USA). To detect WT1, Bax, and
bcl-2, the membranes were blocked for 1 h at room
temperature in TBS-0.1% Tween containing 5% fat-free
dry milk, and incubated with anti-WT1 antibody (C19;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
anti-Bax antibody (B-9, SC 7480), or anti-bcl-2 antibody
(C-2, SC 7382) diluted 1:500 for 3 h at room tem-
perature. The membranes were washed and blotted with
peroxidase-conjugated donkey anti-rabbit secondary anti-
body (1:8,000) (Boehringer Mannheim, Indianapolis, IN,
USA) for WT1, or with peroxidase-conjugated goat anti-
mouse secondary antibody (1:5,000) (W402B, Promega,
Madison, WI, USA) for Bax and bcl-2. Immunolabeled
proteins were detected using an enhanced chemilumines-
cence kit (Amersham Pharmacia Biotech). The bands cor-
responding to WT1, Bax, and bcl-2 proteins (respectively,
52, 22, and 26 kDa) are indicated in Figure 1C and D.
To ensure the cell lysates were loaded equally, the blots
were stripped and incubated with β-actin (1:1,000 dilution;Figure 1 Regulation of Bax and bcl-2 expression by WT1 in immature
levels in GCs transfected with increasing amounts of WT1 (−KTS) (10, 30, 10
each reaction. Values are calculated as fold changes relative to contro
experiments, each performed in triplicate. CT, cells transfected with em
of (C) Bax and (D) bcl-2 protein levels. Lysates were immunoblotted with an
(B-9, SC 7480), or anti-bcl-2 antibody (C-2, SC 7382). Arrows indicate bands c
(42 kDa), respectively.Sigma, St. Louis, MO, USA). Data were collected from at
least two independent experiments.
Analyses of cell viability and apoptosis
Cell viability was determined using an MTT [3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide]
assay kit (Cayman Chemical Company, Ann Arbor, MI,
USA). The conversion of MTT into the aqueous soluble
formazan product is accomplished by dehydrogenase
enzymes found in metabolically active cells. GCs were
cultured in McCoy 5a serum-free medium with or with-
out FSH or 10% FBS for 24 h after transfection. After
addition of tetrazolium salt solution and incubation at
37?C for 2 h, the quantity of the formazan product was
measured by the absorbance at 570 nm. The experiment
was repeated three times, and the data were expressed as
fold changes relative to the control values measured with
empty vector-transfected cells cultured for 24 h in the
absence of serum.
Apoptosis was subsequently assessed with the caspase
3/7 activity assay using a luminescence assay kit (Caspase-
Glo 3/7 assay; Promega). GCs were cultured in McCoy 5a
serum-free medium with or without FSH or 10% FBS for
24 h after transfection. Then proluminescent Caspase-Glo
3/7 reagent was added to each well, and the cells were
gently mixed and incubated at room temperature for 1 h.rat GCs. Real-time RT-PCR analysis of (A) Bax and (B) bcl-2 mRNA
0 ng/well) or WT1(+KTS) (100 ng/well). GAPDH was used to normalize
l (CT), and are expressed as the mean ? SD of three independent
pty vector. *p < 0.05 compared to control. Western blot analysis
ti-WT1 antibody (C-19; Santa Cruz Biotechnology, Inc.), anti-Bax antibody
orresponding to WT1 (52 kDa), Bax (22 kDa), bcl-2 (26 kDa) and β-actin
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ometer (Analytical Luminescence Laboratory, San Diego,
CA, USA). As for the MTT assay, the data were expressed
as fold changes relative to the control.
Terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end labeling (TUNEL) assay
Apoptosis was analyzed by 3? -end labeling of DNA frag-
ments in situ using the ApopTag In-Situ Apoptosis
Detection kit (Oncor, Gaithersberg, MD) according to
the manufacturer ? s protocol. In addition, we performed
fluorescent staining for WT1 protein to confirm overex-
pression of WT1 in transfected GCs. GCs (1 ? 10 5 cells)
were plated onto 2 ? 2 cm coverslips at 6-well plate and
transfected with WT1 or empty-vector for 6 h and then
serum starved for another 36 ~ 48 h. After then, cells
were fixed with 4% paraformaldehyde for 10 min at
room temperature and washed twice in PBS. The cells
were then incubated with terminal deoxynucleotidyl
transferase and digoxigenin-11 dUTP in a humidified
chamber at 37?C for 1 h or polyclonal anti- WT1 anti-
body (1:100) for 2 h at room temperature. The cells were
washed with PBS and incubated with antidigoxigenin-
fluorescein antibody for 1 h for TUNEL or a Alexa Flour
594 goat antirabbit IgG (1:200)(Invitrogen, Carlsbad,
CA, USA) for 30 min for WT1. The cells were then
washed with buffer and nuclear DNA was counter-
stained with 4?,6-diamidino-2-phenylindole (DAPI)(Vector
Laboratories, Inc., Burlingame, CA, USA). We counted
the number of apoptotic cells using a Leica TCP SP5
confocal microscope (Leica, Heidelberg, Germany). We
randomly selected 4 ~ 6 magnified fields (X200) and
calculated the average number of apoptotic cells per
field. Apoptosis was expressed as the percentage of
TUNEL-positive nuclei per field. These experiments were
repeated five times.
Chromatin immunoprecipitation (ChIP) analysis
ChIP assay was performed on WT1 in the Bax promoter
region using a ChIP kit (Upstate Biotechnology, Inc.,
Lake Placid, NY) according to the manufacturer ? s proto-
col with minor modifications. Briefly, immature rat GCs
(2?10 7) were transfected with WT1(−KTS) using lipofec-
tamine 2000, cultured in McCoy 5a serum-free medium
for 24 h, and cross-linked with 1% formaldehyde for
10 min at room temperature. The reaction was termi-
nated by the addition of glycine (final concentration,
0.125 M) for 5 min at room temperature. Cells were
pelleted by centrifugation and lysed in 1 ml ice-cold lysis
buffer containing protease inhibitor cocktail (Roche
Applied Science, Indianapolis, IN, USA). The lysates were
sonicated on ice at a 250 W power level for 25 min with
15-sec sonication and 30-sec intervals with a Bioruptor
KR (CosmoBio Co., Ltd., Tokyo, Japan) to obtain DNAfragments of an average length of approximately 100?
500 bp. Chromatin was immunoprecipitated overnight at
4?C with anti- WT1 antibody (10 ug/reactions; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) or normal
rabbit IgG (5 ug/reaction; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) as a negative control. Im-
mune complexes were collected using protein G-agarose
slurry for 2 h at 4?C with rotation and sequentially
washed for 3 min each in low salt wash buffer, high salt
wash buffer, LiCl wash buffer, and two washes with Tris/
EDTA buffer. Precipitates were then extracted two times
with elution buffer. Eluates were pooled, and cross-
linking was reversed by incubation at 65?C overnight.
Unbound proteins were digested with proteinase K
(Promega) for 2 h at 45?C, and chromatin was purified
using the DNA Clean-up kit (GeneAll Biotechnology,
Seoul, Korea). DNA was analyzed by PCR using the
primers designed to amplify fragments of the WT1 motif
in the Bax promoter [see Figure 2A, WT1−1497(forward 5? -
GGC CTG CTG CTA CTT CAC AT-3?, reverse 5? -TTT
TAA TCC CAG CCC TCA GA-3? ), WT1−1299(forward 5? -
TAG TCC AGG CTG ACC TCG AA-3?, reverse 5? -ATG
GTG GCC CAT ACC TGT AA-3? ), WT1−1160(forward 5? -
CAT CCT AGG CTG GCT TCA GA-3?, reverse 5? -CCT
TCT CAC CTC ACC ATA CCT C-3? ), WT1−1008(forward
5? -GAG GTA TGG TGA GGT GAG AAG G-3?, reverse 5? -
TCT CTC TCC TCC TTT CCC AAA-3? ), and WT1−239
(forward 5? -ATA TCC CAG GCA AGC TTT GA-3?, re-
verse 5? -GCC GCG GGT ACT AAA TGA AC-3? )]. After
25- to 28-cycle amplification, PCR products were run on a
1.5% agarose gel, stained with ethidium bromide, and visu-
alized under UV light.
Data analysis
All results are expressed as the mean ? SD of duplicate
measurements of triplicate cultures, and each experi-
ment was repeated at least three times. Statistical signifi-
cance was determined by Mann ? Whitney U-test for two
group comparison and Kruskal-Wallis one-way analysis
of variance for multiple group comparisons. Significance
was accepted at p < 0.05.
Results
Effects of WT1 overexpression on basal Bax and bcl-2
transcript and protein levels
To determine whether WT1 regulates the endogenous
expression of pro-apoptotic genes directly, we analyzed
primary GCs expressing either WT1 (+KTS) or WT1
(−KTS). Since insertion or removal of the three amino
acid sequence (KTS) changes the DNA-binding specifi-
city of WT1 [8,9], it was important to compare the ef-
fects of the two isoforms in GCs. Markers of apoptosis
(i.e. Bax or bcl-2) were detected using real time RT-PCR
and Western blotting. Overexpression of WT1 (+KTS)
Figure 2 Evidence of WT1 binding in the Bax promoter region in vivo. (A) Schematic showing the Bax promoter and the target region
tested in ChIP assay. The locations of primers used to amplify DNA fragments spanning WT1 transcription binding sites were designated in the
Bax promoter region. (B) ChIP detection of WT1 transcription factor binding to the Bax promoter region in immature GCs. ChIP assays were
performed using DNA extracted from GCs obtained at 36? 48 h after transfection. One tenth of the chromatin was kept as input DNA control
(Input) before immunoprecipitation. Immunoprecipitations were performed with WT1 antibody, or normal rabbit IgG served as a negative control.
DNAs were analyzed by PCR using primers indicated previously. WT1−1299 (210 bp) and WT1−1160 (212 bp) DNA fragments containing WT1
transcription factor binding sites were enriched in chromatin samples immunoprecipitated with WT1 antibody as well as input DNA. A
representative gel picture from at least four independent experiments is shown.
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corresponding immunoreactive bands (52 ~ 54 kDa) are
shown in Figure 1C and D (upper lane). Total RNA
was isolated from the cells expressing either the WT1
(−KTS) or the WT1 (+KTS) isoform. Interestingly, in the
GCs expressing the WT1 (−KTS) isoform, we observed
significantly decreased levels of Bax transcripts, while
there was no significant effect in the GCs expressing
WT1 (+KTS) (Figure 1A). It was important to determine
whether this decrease led to a subsequent decline in the
levels of Bax protein. To address this question, total pro-
teins were isolated from GCs expressing either WT1
(+KTS) or WT1 (−KTS) proteins. Consistent with the
findings of real time RT-PCR, the cells overexpressing
WT1 (−KTS) contained less Bax protein than the empty
vector-transfected cells (Figure 1C), while the GCs ex-
pressing the WT1 (+KTS) isoform had the control level
of Bax (Figure 1C). The levels of bcl-2 transcripts and
protein were not altered by overexpression of either of
the two WT1 isoforms (Figure 1B and D).
Effect of WT1 overexpression on GC viability under
serum deprivation
Despite its tumor suppressor function, WT1 prevents
programmed cell death in some cell types but promotes
it in others [10-12]. Thus, we were interested to find out
whether WT1 protein altered sensitivity to apoptotic
stimuli. To investigate the role of WT1 in GC viability,
we employed the MTT assay to monitor the activity ofmitochondrial reductase [13]. GCs transfected with WT1
were cultured with or without serum or FSH for 24 h.
The purpose of removing the serum was to induce spon-
taneous onset of GC apoptosis because serum has shown
to contain growth factors associated with a significant de-
crease in pro-apoptotic proteins [14]. On the other hand,
FSH is the main physiological regulators of ovarian follicle
survival and sufficient FSH concentrations are critical for
survival of follicles [15,16].
As shown in Figure 3A, the effect of WT1 (−KTS)
overexpression on MTT activity was significant (p = 0.029
compared to the control), and as potent as that of 10%
FBS. In addition, we confirmed the role of FSH and serum
as survival factors in immature GCs; addition of serum had
a more potent effect than FSH, which may be related to
the lower numbers of FSH receptors in immature GCs.
Overexpression of WT1 (+KTS) also increased MTT activ-
ity, but the effect was not statistically significant (p > 0.05).
Effects of WT1 overexpression on apoptosis in
cultured GCs
To see whether the enhanced cell viability was due to
suppression of apoptosis, we analyzed apoptosis quanti-
tatively by measuring caspase 3/7 activity. After incuba-
tion of the transfected cells for approximately 16 ? 24 h,
GCs were cultured with or without serum or FSH. The
enzymatic activities measured in each group were com-
pared with the activities in the cells cultured in serum-
free conditions (control). As shown in Figure 3B, in the
Figure 3 Regulation of cell viability by overexpression of WT1 (−KTS), but not WT1 (+KTS). (A) MTT assays of immature rat GCs transfected
with one of the two WT1 isoforms. GCs transfected with WT1 or empty vector were incubated with or without serum for 24 h. Some cells were
treated with FSH (50 ng/mL) as a positive control for survival factors. After the cells were incubated with tetrazolium salt solution for 2 h, the
quantity of formazan product was determined from the absorbance at 570 nm. Each bar represents the fold change compared to control (CT).
(B) analysis of caspase 3/7 activity. GCs transfected with WT1 or empty vector were incubated with or without serum. Some cells were treated
with FSH (50 ng/mL) as a positive control for apoptosis suppressors. 24 h later, caspase 3/7 activity was measured with the bioluminescence
assay. (C) Immunoblot analysis of WT1 protein in cultured GCs lysates to confirm WT1 overexpression. Bands corresponding to WT1 (52 kDa), and
β-actin (42 kDa), respectively. CT, empty vector-transfected cells cultured without serum for 24 h. WT1 (−KTS) (100 ng/well); WT1 (+KTS) (100 ng/well);
FBS, 10% fetal bovine serum. Data are expressed as the mean ? SD of three separate experiments. *p < 0.05 compared to control.
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0.8-fold of the activity in cells cultured in serum-free
conditions (control) (p > 0.05). Interestingly, overexpres-
sion of WT1 (−KTS) caused an approximately 0.5-fold
decrease in caspase-3/7 activity compared to the cells
cultured in serum-free conditions (p = 0.0026), indicating
that WT1 (−KTS) had an inhibitory effect on GC apop-
tosis induced by serum deprivation. Moreover, this
inhibitory effect was as potent as that of FSH. WT1
(+KTS) overexpression also decreased caspase 3/7 activ-
ity as much as 10% FBS, although the resulting activity
was not significantly different from the control (p > 0.05).
In summary, the expression of WT1 (−KTS) in GCs seems
to confer significant resistance to apoptotic cell death in-
duced by serum deprivation, an effect as potent as FSH
treatment.
In addition, the effects of WT1(−KTS) on the inci-
dence of GC apoptosis were determined by TUNEL
staining in GCs (Figure 4). This was carried out in trans-
fected GCs induced to undergo apoptosis in serum-free
cultures [14]. WT1 protein expression was profoundly
increased in WT1 transfected GCs and confirmed effi-
cient transfection (Figure 4A). The percentage of apop-
totic cells significantly decreased at 36 ? 48 h of culturein WT1 transfected cells as compared with the control
(CT vs. WT1; 41.9 ? 15.7% vs. 19.7 ? 10.3%)(P < 0.01)
(Figure 4B). These results showed that apoptosis was
suppressed in GCs transfected with WT1 compared with
the control, suggesting that WT1 is involved in GCs
survival by regulating apoptosis.
Role of WT1 (−KTS) in suppressing Bax promoter activity
The presence of potential binding elements for WT1 in
the Bax promoter suggested that WT1 might affect Bax
expression in the ovary (Figure 2A). Transient transfec-
tion assays were performed to determine whether the
decrease in Bax levels, observed when WT1 (−KTS) was
overexpressed, was due to the ability of WT1 (−KTS) to
reduce Bax promoter activity. For comparing luciferase
activities, cells transfected only with the Bax promoter
construct, without any treatment, constituted the control
group. Increased level of WT1 protein expression in
WT1 transfected GCs was confirmed (Figure 5B). As
shown in Figure 5A, the WT1 (−KTS) transfected cells
displayed a significantly reduced level of Bax promoter
activity (0.6-fold of the control group) (p < 0.05). As ex-
pected, FSH significantly suppressed Bax promoter ac-
tivity (0.5-fold of the control) and the addition of FSH to
Figure 5 WT1 (−KTS) suppression of Bax promoter activity in immature rat GCs. (A) Cells were co-transfected with the Bax promoter luciferase
reporter construct (250 ng/well) and either WT1 (+KTS) or (−KTS) (100 ng/well), and cultured for 24 h. FSH (50 ng/mL) was used as a positive control for
Bax repressor. Cell lysates were assayed for the activity of the luciferase reporter gene. Luciferase activity is expressed as relative light units (RLU) and
normalized based on β-gal activity in co-transfected cells. Values are calculated as fold-changes relative to control (CT), and are expressed as
the mean ? SD of three independent experiments, each performed in triplicate. (B) Immunoblot analysis of WT1 protein in cultured GCs lysates
to confirm WT1 overexpression. Bands corresponding to WT1 (52 kDa), and β-actin (42 kDa), respectively. CT, control (cells transfected with Bax
promoter only). *p < 0.05 compared to control; **p < 0.05 compared to FSH.
Figure 4 WT1 suppresses granulosa cell apoptosis. (A) GCs transfected with WT1(−KTS) or empty vector were stained with TUNEL or WT1
antibody to visualize apoptotic cells (green) or WT1 protein (pink: merge with DAPI) and counterstained with DAPI to confirm nuclear status
(blue). Representative fluorescence confocal microscopy images are shown. Magnification; X100 or X200. (B) Frequency of TUNEL-positive nuclei
in GCs transfected with empty vector or WT1(−KTS). Data represent mean ? SD of five independent experiments. CT, empty vector-transfected
cells; WT1, GCs transfected with WT1 (−KTS)(100 ng/well). * p < 0.05 vs. EV.
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moter activity (0.3-fold of the control) (p < 0.01). Con-
versely, WT1 (+KTS) failed to affect Bax promoter
activity. Collectively, these results provide evidence that
the Bax promoter is transcriptionally down-regulated by
the WT1 (−KTS) isoform but not by the WT1 (+KTS)
isoform.
Identification of the WT1(−KTS) binding sites on the Bax
promoter region in GCs
To determine whether WT1 directly regulates Bax ex-
pression, we first analyzed the putative promoter region
[~2.7-kb upstream of transcription start site] of the Bax
gene using a web-based transcription factor prediction
program. This analysis revealed the presence of several
putative WT1 binding sites, with five consensus binding
sites (Figure 2A). To examine whether WT1 specifically
binds to these candidate sites in the Bax promoter
in vivo, ChIP assays were performed using immature
GCs. PCR fragments [210 bp (−1394/-1185), 212 bp
(−1253/-1042) and 172 bp (−331/-160)] containing the




the proximal promoter region were enriched in chroma-
tin samples treated with WT1 antibody compared with
normal rabbit IgG, demonstrating the in vivo binding of
WT1 on the TCC repeats of the middle region of
Bax promoter [−1160(TCC)2,
−1299(TCC)7] and the
GNGGGGGGG in the proximal (Figure 2B), whereas no





The apoptotic death of GCs underlies the initiation and
progression of follicular atresia [17]. A number of factors
are thought to regulate the apoptosis of ovarian GCs
[18], but relatively little is known about the survival of
preantral follicles compared with the later stages of de-
velopment. Although responsiveness to FSH plays a crit-
ical role in the follicular transition and follicle survival in
the ovary [15,16], it is insufficient to prevent apoptosis
during the initial, FSH-independent stages. In fact, the
early antral follicles are more susceptible to apoptosis
than preantral follicles [1,19]. Thus, our main aim was
to identify how early-stage follicles remain healthy and
non-apoptotic. To this end, we investigated the effects of
WT1 on the expression of pro-apoptotic genes and on
cell survival in immature GCs.
It is widely accepted that the relative levels of tumor
suppressors, apoptotic proteins, and survival factors in
GCs determine the fates of early-stage follicles [20].
WT1, a member of the zinc-finger family of transcrip-
tion factors, is highly expressed in GCs in early-stage
follicles. Its expression undergoes dynamic changes duringfolliculogenesis, alongside changes in the spatial and tem-
poral expression of the FSH receptor gene [3]. Once the
early antral follicles begin expressing FSH receptors, they
become dependent on FSH stimulation for survival [1],
and WT1 expression declines [2]. This stage-dependent
regulation of WT1 and its target genes, including the FSH
receptor [4], suggests that a functional link between WT1
and FSH signaling promotes the transition of follicles from
small to more differentiated. The role of FSH as the main
physiological regulator of ovarian follicle cell proliferation
and survival is well established [18]. Since FSH acts as a
key survival factor for the growing follicles [1], the small
increase in cell numbers observed after FSH treatment
(Figure 3) may be the result of a low responsiveness to
FSH of immature GCs obtained from small preantral folli-
cles. As a follicle grows, expression of the FSH receptor
continues to increase [21] and FSH can exert its effects on
downstream molecules, including WT1 [22]. Therefore,
given that WT1 enhanced GC survival in this study, it is
reasonable to assume that WT1 plays a role in preventing
apoptosis during the FSH-independent stages, until FSH
takes on that role.
Bcl-2 family proteins, including bcl-2 and Bax, regulate
the release of pro-apoptotic factors, and in particular of
cytochrome c, from the mitochondrion into the cytosol
[23], which is an almost universal event during apoptotic
cell death. The product of the bcl-2 gene prevents apop-
tosis, and Bax opposes bcl-2 action [24]. The relation-
ship between WT1 and the Bcl-2 family of proteins
during GC apoptosis has not been well studied. Previ-
ously, WT1 activation was shown to regulate several
pro-apoptotic genes, including Bax, in non-gonadal cells
[10,12,25]. Bax expression was shown to be regulated
differently depending on cell lineage and isoforms. For
instance, Bax expression was significantly decreased by
either of the two WT1 isoforms in breast cancer cells
[25], whereas it was not changed in leukemic cells [11].
In the cells obtained from the ovary or the uterus, the
WT1 (−KTS) isoform was reported to be more potent
than WT1 (+KTS) as a regulator of ovarian marker
genes [3,4]. Likewise, our results demonstrated a sup-
pressive role of WT1 (−KTS), but not of WT1 (+KTS),
on Bax expression in GCs. A possible explanation is that
the KTS insertion disrupts the critical spacing between
the zinc fingers resulting in a severe reduction of bind-
ing to the consensus WT1 binding site [26]. However, a
direct interaction between WT1 and the Bax promoter
has not been previously demonstrated. The WT1 (−KTS)
isoform binds to GC-rich sites (known as EGR1, WRE,
and WTE) and to (TCC)n repeat elements [27]. An ana-
lysis of genomic sequences demonstrated the presence
of potential binding elements for WT1 (−KTS) in the
Bax promoter region, as shown in Figure 2A. We also
showed that Bax inhibition coincided with increasing levels
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ther inhibited Bax promoter activity in GCs, as shown in
Figure 5A. In addition, our results demonstrated that WT1
(−KTS) down-regulates endogenous Bax levels by tran-
scriptionally regulating the Bax promoter through a high-
affinityWT1-binding site (Figure 2B).
On the other hand, WT1 appears to have no role in
bcl-2 expression in GCs, even though it was shown to
either suppress or activate bcl-2 in non-gonadal cells
[10,28]. Apoptosis in follicles in vitro is mainly associ-
ated with a marked increase in Bax levels with no
significant change in bcl-2 [29]. Since the levels of
bcl-2 stay relatively constant, it is likely that the WT1-
enhanced cell viability is due to the markedly reduced
expression of Bax (Figure 1). As WT1 is expressed in
the GCs of primordial and primary follicles that are poor
in FSH receptors, it is unlikely that FSH plays an import-
ant role in regulating Bax expression at this stage. This,
in turn, suggests that WT1 may change the apoptotic
set point by up- or down-regulating the expression of
pro-apoptotic proteins, in particular Bax. Although the
precise mechanism by which other co-expressed factors
down-regulate the expression of Bax still needs to be
determined, the finding that WT1 suppresses Bax accu-
mulation in GCs provides important insight into the
regulation of apoptosis during early folliculogenesis.
The anti-apoptotic role of WT1 during urogenital de-
velopment was first established by Kreidberg et al. [5].
To investigate the role of WT1 in GC apoptosis, serum
was removed to induce spontaneous apoptosis [14].
Consistent with the role of WT1 in the regulation of
ovarian FSH receptor expression in GCs [4], WT1
(−KTS) seems to play a significant role in enhancing cell
survival, although both isoforms increased the pro-
portion of viable cells under serum deprivation con-
ditions (Figure 3A). In addition, the observations of
decreased TdT-positive cells, marker of DNA fragmenta-
tion (Figure 4), are in agreement with previous reports
on the anti-apoptotic action of WT1 in extragonadal cells
[5]. Another important regulator of the apoptotic process
is the caspase family of proteases [18]. Increased perme-
ability of mitochondria under the influence of Bax results
in the activation of caspases 3 and 7 as the final common
pathway of apoptosis [24,30]. In addition to confirm-
ing Bax regulation by WT1 in GCs, we demonstrated
anti-apoptotic effects of WT1 (−KTS). According to a
previous report, WT1 (−KTS) induced apoptosis by up-
regulating caspase 3 in osteosarcoma cells [31]. Con-
versely, WT1 (−KTS) was found to inhibit apoptosis in
GCs by down-regulating caspase 3 as strongly as FSH
(Figure 3B). We also observed an anti-apoptotic effect of
WT1 (+KTS), although it was not statistically significant.
WT1 (+KTS) has been reported to inhibit apoptosis by
down-regulating Bax in several human leukemic cells [11].However, WT1 (+KTS) may affect GC survival via a differ-
ent mechanism from WT1 (−KTS), as it played no role in
the regulation of Bax expression (Figure 1).
To our knowledge, this is the first study demonstrating
the role of WT1 in GC apoptosis and survival. Our ob-
servations corroborate previous reports on the anti-
apoptotic role of WT1 in non-gonadal cells [11]. We
suggest that WT1 activation is necessary to maintain GC
survival during the early stages of follicle development,
and that WT1 can influence apoptosis at a number of
points, including regulation of an upstream activator
(Bax), and downstream effectors (caspases 3 and 7).
Thus, WT1 may be a key regulator responsible for en-
hancing GC survival, with a fine-tuning role during the
early stages, which take place in a relatively poor vascu-
lar environment similar to serum starvation. As more
blood supply reaches the follicles and factors from the
serum perfuse the cells, WT1 may counteract some pro-
apoptotic factors until the cells can sufficiently respond
to FSH. A better understanding of how apoptosis is reg-
ulated during the early FSH-independent follicular stages
may improve our ability to manipulate fertility and the
timing of the menopause.
Conclusion
These findings suggest that activation of WT1 is neces-
sary for maintenance of GC survival during early stage
of follicles and WT1 can play a role in protecting apop-
tosis through the regulation of upstream activator (Bax),
as well as through regulation of downstream effecter
(caspases 3 and 7). Collectively, our findings allow us to
draw the conclusion that the fate of the follicles during
their development may be determined by the changing
pattern of WT1 and FSH receptor expression.
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